<DOC>
	<DOCNO>NCT02986698</DOCNO>
	<brief_summary>The investigator aim evaluate safety utero hematopoietic stem cell transplantation fetuses alpha-thalassemia major perform time utero transfusion red blood cell .</brief_summary>
	<brief_title>In Utero Hematopoietic Stem Cell Transplantation Alpha-thalassemia Major ( ATM )</brief_title>
	<detailed_description>Alpha thalassemia major ( ATM ) almost universally fatal utero represent orphan disease unmet need effective therapy . The current treatment allow fetus bear perform utero transfusion ( IUT ) red blood cell treat anemia avoid complication hydrops fetal demise . Often , affect pregnancy undergo elective termination diagnosis . Cases prenatal diagnosis ATM receive IUT survive birth ultimately require lifelong monthly blood transfusion bone marrow transplant , suitable donor identify . This phase 1 clinical trial demonstrate safety , feasibility efficacy perform utero stem cell transplantation fetus affect ATM . The investigator aim recruit ten participant prenatal diagnosis ATM . Participants undergo bone marrow harvest utero transfusion combine maternal stem cell . Transplanting maternal cell fetus take advantage exist maternal-fetal tolerance pregnancy . Hematopoietic stem cell ( HSC ) transplantation fetus take advantage develop fetal immune system induce tolerance transplanted cell without use condition immunosuppression . Performing stem cell transplantation time IUT minimize additional procedural risk fetus . The investigator hope demonstrate safe feasible perform utero stem cell transplantation . Additionally , investigator want demonstrate postnatal chimerism maternal cell , bone marrow transplant remain necessary delivery , condition immune suppression require .</detailed_description>
	<mesh_term>Thalassemia</mesh_term>
	<mesh_term>Hemoglobinopathies</mesh_term>
	<mesh_term>beta-Thalassemia</mesh_term>
	<mesh_term>alpha-Thalassemia</mesh_term>
	<mesh_term>Hydrops Fetalis</mesh_term>
	<criteria>Male female fetuses 18 week 0/7 day 25 week 0/7 day gestation diagnosis alphathalassemia major chorionic villus sampling ( CVS ) , amniocentesis , cordocentesis identification parent genetic carrier , identification fetal anemia sign impend hydrops , parent elect pursue utero transfusion , willing undergo subsequent IUT remainder gestation . parent must consent fetal autopsy event fetal demise adequate bone marrow harvest maternal participant condition inclusion Fetal Subject Fetal participant exclude second major anatomic anomaly ( related underlie thalassemia ) contribute significant morbidity mortality risk , echocardiogram ultrasound finding indicate high risk fetal demise fetal intervention . Maternal Subject Maternal participant exclude one morbidity would preclude bone marrow harvest fetal intervention include , limited , morbid obesity BMI &gt; 35 , maternal cardiac disease , mirror syndrome , symptomatic maternal anemia , develop preterm premature rupture membrane ( PPROM ) active preterm labor ( PTL ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Weeks</minimum_age>
	<maximum_age>25 Weeks</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>intrauterine transfusion</keyword>
	<keyword>utero human stem cell transplantation</keyword>
</DOC>